Opinion|Videos|July 7, 2026

From Observation to Treatment: The Role of Caregivers and Overcoming VMAT2 Inhibitor Complexities

The panelists examined the valuable role caregivers can play in identifying early TD movements, noting that patients often mask symptoms during office visits but may not do so around loved ones, and that caregiver education through accessible resources, such as sponsored videos, can help them recognize subtle signs

In this episode, 'From Observation to Treatment: The Role of Caregivers and Overcoming VMAT2 Inhibitor Complexities,' the expert psychiatry pharmacists explored the following questions:

What role can caregivers play in identifying early tardive dyskinesia (TD) movements that may be missed in office visits?

How can healthcare providers overcome perceived complexities in initiating vesicular monoamine transporter 2 (VMAT2) inhibitors?

The panelists examined the valuable role caregivers can play in identifying early TD movements, noting that patients often mask symptoms during office visits but may not do so around loved ones, and that caregiver education through accessible resources, such as sponsored videos, can help them recognize subtle signs. Melissa Cloyd and Jamie Kneebusch discussed the value of video documentation to track symptom progression over time, which can motivate patients to continue treatment and reinforce adherence by allowing them to visualize improvement that they may not otherwise perceive. The panelists then addressed strategies for overcoming perceived complexities in initiating VMAT2 inhibitor therapy, including building relationships with specialized mental health pharmacies that understand insurance and prior authorization requirements, providing patients with step-by-step flow sheets, and recognizing that many perceived drug interaction concerns are manageable rather than true contraindications.

Throughout the conversation, the experts provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Our next episode, 'Communicating Early Treatment Benefits and Navigating VMAT2 Inhibitor Dosing in Tardive Dyskinesia,' further explores tardive dyskinesia, highlighting communication strategies that help patients understand the benefits of starting TD treatment early, as well as the dosing differences between VMAT2 inhibitors and their importance in special patient populations.


Latest CME